Ventripoint Installs Whole Heart Analysis System At Toronto General Hospital

Ventripoint Diagnostics (TSXV: VPT) has seen its technology installed at the largest cardiac centre in Canada. The company announced this morning that its VMS+3.0 whole heart analysis system has seen its first install at the Peter Munk Cardiac Center in Toronto, Canada.

The Peter Munk Cardiac Centre resides at the University Hospital Network’s Toronto General Hospital. The addition of the device enables the Centre to be able to assess heart function in all four chambers of the heart via an echocardiogram, rather than that of an MRI. The technology enables the Hospital to manage and conduct future research in patients with right heart failure.

Commenting on the installation of the system, Executive Chairman of Ventripoint Dr George Adams stated, “just as it is PMCC’s mission to use the best equipment to optimize patient care, it has always been the Company’s mission to create “best-in-breed” equipment to assist clinicians and medical personnel in a myriad of clinical settings to accurately assess heart function. We feel incredibly privileged to have this world-leading hospital adopt our system.”

The install marks the third install at a top-tier hospital in the last five weeks, while also being the fifth hospital in Canada to install the new VMS+3.0 system. Previously, the company installed a system at the Erasmus-Sophia University Medical Center in the Netherlands, one of the leading cardiac centres in Europe, as well as at the University of Texas MD Anderson Cancer Center, one of the worlds most respected cancer centres.

To date, a total of 10 VMS+3.0 systems have been delivered, with the company expecting to install units in additional leading cardiac centres before the end of the year.

Ventripoint Diagnostics last traded at $0.10 on the TSX Venture.


FULL DISCLOSURE: Ventripoint Diagnostics is a client of Canacom Group, the parent company of The Deep Dive. The company has been compensated to cover Ventripoint Diagnostics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Tudor Gold x American Creek: Consolidating A Massive Gold Project

Aura Minerals: The Era Dorada Underground PEA

Gold Is Now Smart Money’s End Game | Doug Casey

Recommended

Goliath Resources Expands 2025 Drill Program To 60,000 Metres

Emerita Resources Formally Appeals Administrative Ruling On Aznalcóllar Related To 2017 Complaint 

Related News

Ventripoint Finds Itself In The Right Place At The Right Time

Sometimes when it comes to the markets, the best thing that can happen to a...

Monday, October 5, 2020, 12:45:00 PM

George Adams: COVID-19 Damages The Heart – The Daily Dive

Today’s Daily Dive welcomes back Dr. George Adams, Executive Chairman of VentriPoint Diagnostics (TSXV: VPT)....

Friday, September 17, 2021, 01:30:00 PM

Ventripoint Diagnostics Advances Distribution In Largest Global Market For Heart Disease

Ventripoint Diagnostics (TSXV: VPT) this morning provided an update on its sales and marketing activities...

Tuesday, February 16, 2021, 07:57:55 AM

Ventripoint: Uplisting To The OTCQB – The Daily Dive

Today on the Daily Dive, we are joined by George Adams, Chairman of Ventripoint Diagnostics...

Wednesday, January 19, 2022, 01:30:00 PM

Providing Echocardiography For Companion Animals – The Daily Dive feat George Adams of Ventripoint

Today on the Daily Dive is that of George Adams, CEO of Ventripoint Diagnostics (TSXV:...

Thursday, January 28, 2021, 01:30:00 PM